Inhibition of the insulin-regulated aminopeptidase (IRAP) is a promising therapeutic strategy for neurodegenerative disorders such as Alzheimer's disease, due to its role in cognitive processes. The gene discussed is LNPEP; the disease is early-onset autosomal dominant Alzheimer disease.